Allergan Plc
* Allergan acquires Chase Pharmaceuticals to expand CNS research and development pipeline and build on commitment to Alzheimer’s disease
* Deal for an upfront payment of $125 million
* Allergan to advance CPC-201 into Phase 3 registration study in 2017
* Deal includes additional potential milestone payments related to chase’s lead compound, CPC-201, and certain backup compounds
* Allergan plc – Allergan to advance cpc-201 into phase 3 registration study in 2017 Source text for Eikon: Further company coverage:
Recent Articles on M&A
[su_row] [su_column size=”1/2″] [su_posts template=”templates/teaser-loop.php” posts_per_page=”2″ tax_term=”8,502,19,5,6,4,7″ tax_operator=”0″ order=”desc” orderby=”rand”]s[/su_posts] [/su_column] [su_column size=”1/2″] [su_posts template=”templates/teaser-loop.php” posts_per_page=”2″ tax_term=”8,502,19,5,6,4,7″ tax_operator=”0″ order=”desc” orderby=”rand”]s[/su_posts] [/su_column] [/su_row]Source: Reuters.com